GlassScriptPhysician profile
Bailey G Dryden
NPI 1710537345
$5,235.13
in general payments reported to CMS, 2019-2025
21 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $227 · 2022: $922 · 2023: $1,781 · 2024: $1,015 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $914.33 | 2021-2025 | Caplyta |
| Abbvie INC. | $656.02 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $636.26 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $591.17 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $475.33 | 2022-2025 | Auvelity |
| Alkermes, INC. | $318.81 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Ironshore Pharmaceuticals INC. | $305.74 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $209.97 | 2021-2025 | Hetlioz, Fanapt |
| Collegium Pharmaceutical, INC. | $207.80 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $206.96 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $190.93 | 2022-2024 | Austedo, Uzedy |
| Lundbeck LLC | $117.26 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $107.32 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $68.81 | 2021-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $57.48 | 2021-2023 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $55.07 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $31.90 | 2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $30.95 | 2023 | Trintellix |
| Noven Therapeutics, LLC | $23.34 | 2024 | Xelstrym |
| Tempus Ai, INC | $16.96 | 2024 | |
| Indivior INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Dryden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.